Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The February 2000 Formulary monographs are on gatifloxacin, moxifloxacin, levetiracetam, aspirin/extended-release dipyridamole, and aminolevulinic acid HCl. The DUE is on gatifloxacin.
Get full access to this article
View all access options for this article.
References
1.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Drug approvals for September 1999. September 21, 1999. www.fda.gov/cder/da/da0999.htm
2.
Synercid package literature.Rhone-Poulenc Rorer Pharmaceuticals, Inc; September 1999.
3.
New streptogramin promising against vancomycin-resistant enterococci. Pharm Times.1994 (December): 12.
4.
FassR.J.In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother.1991; 35: 553–9.
5.
ArcherG.L.RP 59500, a new streptogramin highly active against recent isolates of North American Staphylococci. Diagn Microbiol Infect Dis.1993; 16: 223–6.
6.
AndrewsJ.M., WiseR.The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500 against staphylococci and respiratory pathogens. J Antimicrob Chemother.1994; 33: 849–53.
7.
KangS.L.Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an In vitro-infected fibrin clot model. Antimicrob Agents Chemother.1995; 39: 1505–11.
8.
BarriereJ.C.Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antimicrob Chemother.1992; 30(suppl A): 1–8.
9.
AumercierM.RP 59500: A proposed mechanism for its bactericidal activity. J Antimicrob Chemother.1992; 30(suppl A): 9–14.
10.
FinchR.G.Antibacterial activity of quinupristin/dalfopristin: Rationale for clinical use. Drugs.1996; 51(suppl): 31–7.
11.
JamjianC.Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30: 70 ratio) compared to alternative ratios for in vitro testing. Diagn Microbiol Infect Dis.1997; 27: 129–38.
12.
CaronF.Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother.1997; 41: 2749–53.
13.
PechereJ.C.Streptogramins: A unique class of antibiotics. Drugs.1996; 51(suppl 1): 13–19.
14.
ChinN.X., NeuH.C.Post-antibiotic effect of a new streptogramin RP 56500. Eur J Clin Microbiol Infect Dis.1992; 11: 642–5.
15.
LowD.E.Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience. Microbial Drug Resist.1995; 1: 223–34.
16.
VannuffelP., CocitoC.Mechanism of action of streptogramins and macrolides. Drugs.1996; 51(suppl 1): 23–30.
17.
BoswellF.J.The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J Antimicrob Chemother.1994; 33: 1219–22.
18.
BrumfittW.In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J Antimicrob Chemother.1992; 30(suppl A): 29–37.
19.
NougayredeA.Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother.1992; 30(suppl A): 101–6.
20.
PankuchG.Postantibiotic effect (PAE) and postantibiotic sub-MIC effect (PA-SME) of quinupristin/dalfopristin (RP 59500) [abstract]. 37th Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto; September 28–October 1, 1997, A84B.
21.
AeschlimannJrPharmacodynamic analysis of quinupristin/dalfopristin (Q/D) versus vancomycin-resistant Enterococcus faecium (VREF) with differing MBCs using time-kill curve (KC) and post-antibiotic effect (PAE) methods [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto; September 28–October 1, 1997, E136.
22.
AppelbaumP.C.Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/ tazobactam. J Antimicrob Chemother.1993; 32: 223–31.
23.
TenoverF.C., BakerC.N.Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin. J Antimicrob Chemother.1997; 39(suppl A): 81–5.
WilliamsJ.D.Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother.1992; 30: 27–37.
26.
L'HeriteauF.RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and - resistant isogenic pairs of viridans group Streptococci. Antimicrob Agents Chemother.1995; 39: 1425–9.
27.
PankuchG.A.Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin/dalfopristin against gram-positive and -negative organisms. Antimicrob Agents Chemother.1998; 42: 3028–31.
28.
AeschlimannJr, RybakM.J.Pharmacodynamic analysis of the activity of quinupristin/dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother.1998; 42: 2188–92.
29.
SoltaniM.Two distinct mechanisms confer resistance to quinupristin/dalfopristin (Q/D) in satA-Negative Enterococcus faecium (Ef) from animals, raw meat, and hospital patients in the EU. 39th Annual Meeting of American Society of Microbiology. San Francisco, CA; September 24–27, 1999.
30.
BozdoganB., LeclercqR.Combination of resistance mechanisms to streptogramins A and B is required to confer resistance to quinupristin/dalfopristin in Enterococcus faecium [abstract]. 39th Annual Meeting of American Society of Microbiology. San Francisco, CA; September 24–27, 1999.
31.
FantinB.Activity of RP 59500 (quinupristin/dalfopristin) against Enterococcus faecium in vitro and in experimental endocarditis [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology; New Orleans, LA; September 15–18, 1996, B006.
32.
BozdoganB., LeclercqR.Intrinsic and acquired resistance to dalfopristin (Streptogramin A) in Enterococcus spp. [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto; September 28–October 1, 1997, C-79.
33.
MillichapJ.Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Diagn Microbiol Infect Dis.1996; 25: 15–20.
34.
WoodC.A.Resistance to quinupristin/dalfopristin encountered during treatment of infections caused by vancomycin-resistant Enterococcus faecium [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemother (ICAAC). American Society for Microbiology: New Orleans, LA; September 15-18, 1996, LB13.
35.
ChowJ.W.Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis.1996; 24: 90–1.
36.
SambatakouH.In vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother.1998; 41: 349–55.
37.
ZarrouchV.Quinupristin/dalfopristin (Q-D) alone or in combination with rifampin and in experimental endocarditis caused by Staphylococcus aureus H different phenotypes of resistance to quinupristin or dalfopristin [abstract]. 39th Annual Meeting of the American Society of Microbiology. San Francisco, CA; September 24–27, 1999.
38.
KangS.L., RybakM.J.In vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother.1997; 39(suppl A): 33–9.
39.
MessickC.R., PendlandS.L.In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococci. Diagn Microbiol Infect Dis.1997; 29: 203–5.
40.
LorianV., FernandesF.Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother.1997; 39(suppl A): 63–6.
41.
MatsumuraS., SimorA.E.Treatment of endocarditis due to vancomycinresistant Enterococcus faecium with quinupristin/ dalfopristin, doxycycline, and rifampin: A synergistic drug combination. Clin Infect Dis.1998; 27: 1554–6.
42.
LeclercqR.Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother.1992; 30(suppl A): 67–75.
43.
RybakM.J.Pharmacodynamics (PD) of RP 59500 (RP) (quinupristin/dalfopristin) administered by intermittent (I) versus continuous infusion (CI) against Staphylococcus aureus (SA) infected fibrin-platelet clots in an in vivo infection model [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology. New Orleans, LA; September 15–18, 1996, A043.
44.
TurcotteA., BergeronM.G.Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots. Antimicrob Agents Chemother.1992; 36: 2211–5.
45.
FantinB.In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother.1994; 38: 432–7.
46.
FantinB.Critical influence of resistance of streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother.1995; 39: 400–5.
47.
EntenzaJ.M.Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother.1995; 39: 1419–24.
48.
ChambersH.F.Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother.1992; 30(suppl A): 117–22.
49.
BernardE.Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/RP 54476). Eur J Clin Microbiol Infect Dis.1994; 13: 768–71.
50.
EtienneS.D.A phase I, double-blind, placebo controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother.1992; 30(suppl A): 123–31.
51.
BergeronM., MontayG.The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother.1997; 39(suppl A): 129–38.
MoelleringR.C.The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother.1999; 44: 251–61.
54.
NicholsR.Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (oxacillin or vancomycin) in the treatment of complicated gram-positive skin and skin structure infections (CSSSI) [abstract]. International Society of Chemotherapy. Programme and Abstracts of the 20th International Congress of Chemotherapy. Sydney, Australia; 1997, 2319.
55.
BealJ.Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated gram-positive skin and skin structure infections (C-SSSI) [abstract]. International Society of Chemotherapy. Programme and Abstracts of the 20th International Congress of Chemotherapy. Sydney, Australia; 1997, 2318.
56.
NicholsR.L.Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother.1999; 44: 263–73.
57.
RaadI.Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis.1999; 18: 199–202.
58.
LynnW.A.Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet.1994; 344: 1025–6.
59.
MosesJ.Treatment of vancomycin-resistant Enterococcus faecium CAPD-associated peritonitis with intraperitoneal administration of quinupristin/dalfopristin [abstract]. 38th Annual Meeting of American Society of Microbiology. San Diego, CA; September 24–27, 1998, MN-52.
60.
SahgalV.S.Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: Case report. Microbial Drug Resist.1995; 1: 245–7.
61.
FurlongW.B., RakowskiT.A.Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococcus with vanA/vanB resistance patterns. Clin Infect Dis.1997; 25: 164–5.
62.
NachmanS.A.Treatment of vancomycin-resistant Enterococcus faecium central nervous system infection with intrathecal administration of quinupristin/dalfopristin [abstract]. 38th Annual Meeting of American Society of Microbiology. San Diego, CA; September 24–27, 1998, E-167.
63.
DeverL.L.Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): A report of fifteen cases. Microb Drug Resist.1996; 2: 407–13.
64.
CassellJ.RP59500 (quinupristin/ dalfopristin): Three case reports of its use in infection due to Enterococcus faecium. J Infect.1998; 36(3): 324–7.
65.
TushG.M.Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis.1998; 26: 1460–1.
ChowJ.W.Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis.1997; 24: 91–2.
68.
BriggsG.G., FreemanR.K., YaffeS.J.Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk.5th ed.Baltimore, MD: Williams & Wilkins; 1998.
69.
RubinsteinE.Safety and tolerability of quinupristin/dalfopristin: Administration guidelines. J Antimicrob Chemother.1999; 44(Topic A): 37–46.
70.
BallowC.H.Cytochrome P-450 3A4 (CYP3A4) inhibition by quinupristin/dalfopristin (Q/D): Interaction with nifedipine (N) in normal volunteers [abstract]. 38th Annual Meeting of American Society of Microbiology. San Diego, CA; September 24–27, 1998, A-77.
BouanchaudD.H.In vitro and in vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother.1997; 39(suppl A): 15–21.
73.
BetriuC.Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: Comparison with the activities of 14 other agents. Antimicrob Agents Chemother.1999; 43: 2320–2.
74.
RidgwayG.L.The in vitro activity of quinupristin/dalfopristin (RP 59500), RPR106972, erythromycin and doxycycline against isolates of Chlamydia trachomatis, Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto; September 28–October 1, 1997, E158.
75.
GotoS.The in-vitro activity of RP 59500 against gram-positive cocci. J Antimicrob Chemother.1992; 30(suppl A): 25–8.
76.
VerbistL., VerhaegenJ.Comparative in-vitro activity of RP 59500. J Antimicrob Chemother.1992; 30(suppl A): 39–44.
77.
NeuH.C.The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother.1992; 30(suppl A): 83–94.
78.
SchoutenM.A., Hoogkamp-KorstanjeJ.A.A.Comparative in vitro activities of quinupristin/dalfopristin against gram-positive bloodstream isolates. J Antimicrob Chemother.1997; 40: 213–9.
79.
MoutonJ.W.In vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J Antimicrob Chemother.1997; 39(suppl A): 75–80.
80.
Giamarellos-BourboulisE.J.In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium. Eur J Clin Microbiol Infect Dis.1998; 17: 657–61.
81.
PechereJ.C.In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci. J Antimicrob Chemother.1992; 30(suppl A): 15–8.
82.
ShonekanD.Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002 trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. J Antimicrob Chemother.1997; 39: 405–9.
83.
CollinsL.A.In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother.1993; 37: 598–601.
84.
EliopoulosG.M.Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother.1998; 42: 1088–92.
85.
BonillaH.F.Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Microbiol Infect Dis.1996; 25: 127–31.
86.
JonesR.N.Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis.1998; 30: 437–51.
87.
FuchsP.Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Eur J Clin Microbiol Infect Dis.1998; 17: 197–201.
88.
PutnamS.D.In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination. Diagn Microbiol Infect Dis.1997; 28: 139–47.
89.
JorgensenJ.H., McElmeelM.L.Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae. J Antimicrob Chemother.1997; 39(suppl A): 69–73.
90.
BebearC., BouanchaudD.H.A review of the in vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas. J Antimicrob Chemother.1997; 39(suppl A): 59–62.
91.
IzumikawaK.In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae. Antimicrob Agents Chemother.1998; 42: 698–9.
92.
MulazimogluL.In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother.1996; 40: 2428–30.
93.
JonesM.E.Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin/dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacinresistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother.1999; 43: 421–3.
94.
BarrettM.S., JonesR.N.In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species. Diagn Microbiol Infect Dis.1996; 25: 147–9.
95.
Hussain QadriS.M.In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates. Chemotherapy.1997; 43: 94–9.
96.
Von EiffC., PetersG.Comparative in vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother.1999; 43: 569–73.
97.
AldridgeK.E.In vitro anti-staphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother.1992; 36: 854–5.
98.
HobanD.J.In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J Antimicrob Chemother.1992; 30(suppl A): 59–65.
99.
SpanglerS.K.Susceptibilities of penicillin-susceptible and resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother.1992; 36: 856–9.
100.
PankuchG.A.Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother.1994; 38: 2065–72.
101.
ReinertR.R.In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis.1998; 17: 662–5.
102.
BiedenbachD.Comparative in vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin- and macrolide-resistant pneumococci by the Etest [letter]. J Antimicrob Chemother.1996; 38: 553–5.
103.
JohnsonC.C.In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and Enterococci. Diagn Microbiol Infect Dis.1995; 21: 169–73.
